星标 ★ IPO日报 精彩文章第一时间推送 4月7日晚间，上交所官网显示，甬矽电子(宁波)股份有限公司(以下简称"甬矽电子"，688362.SH)发行可转债上会获通过。 2月13日，甬矽电子发布2024年年度业绩快报。公告显示，2024年营业总收入36.05亿元，同比增长50.76%；归属于母公司所有者的净利 润6708.71万元，实现扭亏为盈。 值得一提的是，公司在2022年11月于科创板上市，募集资金11.1亿元。 如今上市不足三年，公司拟再次募资不超过11.65亿元，其中9亿 元拟用于多维异构先进封装技术研发及产业化项目建设，2.65亿元则用于补充流动资金及偿还银行贷款。 融资规模普遍不高 2021年—2023年，甬矽电子实现的营业收入分别为20.55亿元、21.77亿元、23.91亿元，净利润分别为3.22亿元、1.37亿元、-1.35亿元。 可以看出，公司在2022年上市当年就开始业绩下滑，在次年由盈转亏。 制图：佘诗婕 募资11.65亿 据悉，甬矽电子拟募资不超过11.65亿元，每张面值为100元，拟于上海证券交易所上市。 资料显示，甬矽电子主营业务为集成电路的封装与测试，下游客户主要为芯片设计公 ...

Itron, Inc. (ITRI) is partnering with Norwegian utility provider Norgesnett to roll out the first edge computing deployment in the Nordic region. Utilizing Itron’s Grid Edge Intelligence portfolio, which features distributed intelligence (DI)-enabled smart meters, this collaboration marks a major milestone in modernizing the electricity grid.As part of Norgesnett’s Advanced Metering Infrastructure (AMI) strategy, the utility will use DI to boost visibility and control across the distribution system—from sub ...

Keysight Technologies, Inc. (KEYS) recently announced that it has collaborated with Coherent Corp., a leading provider of advanced illumination solutions for 3D sensing applications, to enable tuning, validation and 200G characterization of the latter's new vertical-cavity surface-emitting laser (VCSEL) technology. By enabling higher data rates, the state-of-the-art multimode technology promises to facilitate the deployment of Artificial Intelligence/Machine Learning (AI/ML) services while reducing both pow ...

NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has integrated Arabic as the second international language to its Intelligent Fingerprinting Drug Screening System as part of the Company's multilingual upgrade. The addition of Arabic follows INBS's previously announced expansion plans in the Middle East in early 2025, through its ...

Core Viewpoint - The announcement of 23andMe filing for bankruptcy and selling its genetic genealogy database has raised privacy concerns among its customers, prompting legal alerts regarding data deletion [1][2]. Company Overview - 23andMe, founded in 2006 by Anne Wojcicki, was the first to market direct-to-consumer genetic testing in North America, aiming to provide consumers with health information directly [6]. - The company initially thrived by capitalizing on the growing interest in genealogy and health data, but faced significant challenges, including a major data breach in 2023 that compromised the personal information of approximately 5.5 million users [12][13]. Industry Context - The consumer genetic testing industry has seen a decline in sales due to privacy concerns and market saturation, with a notable drop in demand for genetic genealogy kits over the past five years [9]. - Law enforcement's use of genetic genealogy databases has heightened consumer awareness of potential third-party data usage, leading to increased scrutiny and calls for regulatory measures [10][11]. Financial and Corporate Developments - 23andMe has expanded its operations by acquiring health services and pharmaceutical companies, but its financial stability has been jeopardized by recent events, including the bankruptcy filing [12]. - Potential buyers for 23andMe's database include large pharmaceutical companies, international buyers, and tech firms like Google and Ancestry.com, which could significantly reshape the landscape of genetic data ownership [15][16]. Privacy and Regulatory Issues - The sale of genetic databases raises concerns about changing privacy provisions, with customers uncertain about the long-term protection of their data [18]. - The rapid growth of the direct-to-consumer genetics industry has outpaced regulatory frameworks, leaving consumers vulnerable and anxious about their personal data [19].

Artificial Intelligence (AI) and Machine Learning (ML) play a pivotal role in precision oncology, analyzing vast datasets, identifying patterns and aiding in informed decision-making. Within this domain, digital pathology plays a crucial role, leveraging AI algorithms to detect cancerous cells, classify tumor subtypes and enhance patient outcomes. Among its key focus areas, AI-powered automated image analysis and biomarker identification stand out as major advancements.AI/ML in precision oncology has garner ...

Fulgent Genetics, Inc. (NASDAQ:FLGT) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Melanie Solomon - IR Ming Hsieh - Chairman and CEO Brandon Perthuis - Chief Commercial Officer Paul Kim - CFO Conference Call Participants David Westenberg - Piper Sandler Lu Li - UBS Andrew Cooper - Raymond James Operator Greetings, and welcome to the Fulgent Genetics, Inc. Q4 2024 Conference Call and Webcast. At this time, all participants are in a listen-only mode. A question and answer ...

CareDx, Inc (NASDAQ:CDNA) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Caroline Corner - Investor Relations John Hanna - President and Chief Executive Officer Abhishek Jain - Chief Financial Officer Conference Call Participants Mark Massaro - BTIG Bill Bonello - Craig-Hallum Andrew Cooper - Raymond James Mason Carrico - Stephens Eduardo Martinez - H.C. Wainwright Thomas DeBourcy - Nephron Research Operator Good afternoon, everyone. Welcome to the CareDx, Inc. Fourth Qua ...

本次发行股票拟在创业板上市，创业板公司具有创新投入大、新旧产业融合存在不确定性、 尚处于成长期、经营风险高、业绩不稳定、退市风险高等特点，投资者面临较大的市场风险。 投资者应充分了解创业板的投资风险及本公司所披露的风险因素，审慎作出投资决定。 佛山市蓝箭电子股份有限公司 FOSHAN BLUE ROCKET ELECTRONICS CO.,LTD. （佛山市禅城区古新路 45 号） 首次公开发行股票并在创业板上市 招股说明书 保荐人（主承销商） （海口市南宝路 36 号证券大厦 4 楼） 创业板投资风险提示 佛山市蓝箭电子股份有限公司 招股说明书 声 明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发行 人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其 对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任 何与之相反的声明均属虚假不实陈述。 根据《证券法》规定，股票依法发行后，发行人经营与收益的变化，由发行 人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行承担 股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风险。 1- ...

本次发行股票拟在创业板上市，创业板公司具有创新投入大、新旧产业融合存在不确定性、 尚处于成长期、经营风险高、业绩不稳定、退市风险高等特点，投资者面临较大的市场风险。 投资者应充分了解创业板的投资风险及本公司所披露的风险因素，审慎作出投资决定。 佛山市蓝箭电子股份有限公司 FOSHAN BLUE ROCKET ELECTRONICS CO.,LTD. （佛山市禅城区古新路 45 号） 招股意向书 （海口市南宝路 36 号证券大厦 4 楼） 创业板投资风险提示 首次公开发行股票并在创业板上市 保荐人（主承销商） 佛山市蓝箭电子股份有限公司 招股意向书 声 明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发行 人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其 对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任 何与之相反的声明均属虚假不实陈述。 根据《证券法》规定，股票依法发行后，发行人经营与收益的变化，由发行 人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行承担 股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风险。 1- ...